Physician
MT. Auburn Urgent Care, LLC
MT. Auburn Urgent Care, LLC was paid $3.01M by Medicaid between Jan 2018 and Dec 2024, across 38 billing codes. Its largest line is K1034, Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count — 29% of everything it billed.
33Billing provider infoMT. AUBURN URGENT CARE, LLC
CINCINNATI, OH 45219
CINCINNATI, OH 45219
33aNPI1063855294assigned 04/08/2013
33bProvider typeFamily Medicine Physician
28Total paid$3.01M
24GClaims73,148
24DCodes billed38
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Ohio
Rank by total paid#35 of 739
Median peer was paid$30K
This provider vs. median102×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 4,523 | $170K | |
| 2019 | 4,383 | $172K | |
| 2020 | 3,847 | $129K | |
| 2021 | 5,700 | $168K | |
| 2022 | 13,555 | $463K | |
| 2023 | 16,770 | $612K | |
| 2024incomplete | 24,370 | $1.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 29% | 12,992 | 11,196 | $885K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 14,130 | 12,996 | $621K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 18% | 2,636 | 2,362 | $528K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 9.7% | 5,898 | 5,649 | $293K |
| 87529 | 3.4% | 2,292 | 2,055 | $102K | |
| 87481 | 2.4% | 2,105 | 1,882 | $72K | |
| 87563 | 2.1% | 2,041 | 1,827 | $62K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.7% | 2,291 | 2,053 | $52K |
| 87640 | 1.7% | 2,413 | 2,166 | $51K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 2,289 | 2,050 | $47K |
| 87653 | 1.5% | 2,086 | 1,870 | $47K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.0% | 2,206 | 1,971 | $31K |
26 more codes
| 87511 | <1% | 2,298 | $29K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,329 | $27K |
| 81514 | <1% | 751 | $26K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,598 | $25K |
| 81025 | <1% | 4,180 | $17K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 253 | $16K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 336 | $15K |
| 87581 | <1% | 395 | $9K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,071 | $8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 139 | $7K |
| 87498 | <1% | 281 | $6K | |
| 87486 | <1% | 281 | $6K | |
| 81003 | <1% | 4,900 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 123 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 147 | $3K |
| 87541 | <1% | 145 | $3K | |
| 87641 | <1% | 145 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 318 | $3K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 78 | $2K |
| 87634 | <1% | 320 | $2K | |
| 81002 | <1% | 514 | $997.89 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 72 | $818.37 |
| 99384 | <1% | 13 | $700.00 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 31 | $366.25 |
| 87088 | <1% | 38 | $200.02 | |
| 00000 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRADFORD, DAVID (OWNER)